550 related articles for article (PubMed ID: 18996035)
21. Prognostic factors and therapeutic results in multiple myeloma.
Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
[TBL] [Abstract][Full Text] [Related]
22. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
24. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
25. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
Rebmann V; Schütt P; Brandhorst D; Opalka B; Moritz T; Nowrousian MR; Grosse-Wilde H
Clin Immunol; 2007 Apr; 123(1):114-20. PubMed ID: 17218152
[TBL] [Abstract][Full Text] [Related]
26. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
28. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
29. DNA-image cytometry and clinical staging systems in multiple myeloma.
Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
[TBL] [Abstract][Full Text] [Related]
30. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
[TBL] [Abstract][Full Text] [Related]
31. Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis.
Bakoush O; Segelmark M; Torffvit O; Ohlsson S; Tencer J
Nephrol Dial Transplant; 2006 May; 21(5):1263-9. PubMed ID: 16449276
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
35. Plasma cell proliferation in monoclonal gammopathy: relations with other biologic variables--diagnostic and prognostic significance.
Ffrench M; Ffrench P; Remy F; Chapuis-Cellier C; Wolowiec D; Ville D; Bryon PA
Am J Med; 1995 Jan; 98(1):60-6. PubMed ID: 7825620
[TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma in the region of Bursa, Turkey: a retrospective analysis.
Ozkalemkaş F; Ali R; Tunali A; Ozkocaman V; Ozyardimci C; Ozçelik T
J Environ Pathol Toxicol Oncol; 1996; 15(2-4):267-70. PubMed ID: 9216819
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
39. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H
Clin Cancer Res; 2002 Nov; 8(11):3377-82. PubMed ID: 12429624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
